

Laurie Bartlett Keating is Executive Vice President and Chief Legal Officer of Alnylam

Pharmaceuticals where she also has responsibility for public policy and government relations, and is a member of the Board of Directors of Imbria Pharmaceuticals. She joined Alnylam in 2014 with more than 25 years of executive experience at high technology and biotechnology companies. Prior to joining Alnylam, Laurie served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company's global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder, the first CEO, and a member of the Board of Directors of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high growth technology companies, including Iomega Corporation and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie's tenure on the management team. Based on her leadership at Sybase, she was named as one of the 45 most influential in-house lawyers in the United States under the age of 45. Laurie has a Doctor of Jurisprudence from the University of California, Hastings College of the Law, and a Bachelor of Arts in Economics from the University of California at Berkeley.